Table of Content

Open Access iconOpen Access

ARTICLE

How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?

Richard Choo1,2, Sarat Chander1,3, Cyril Danjoux1, Gerard Morton1, Andrew Pearce1, Gerrit Deboer1, Ewa Szumacher1, Andrew Loblaw1, Patrick Cheung1, Tony Woo1

1 Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
2 Mayo Clinic, Rochester, Minnesota, USA
3 Wellington Cancer Centre, Wellington Hospital, Wellington, New Zealand
Address correspondence to Dr. Richard Choo, Division of Radiation Oncology, Mayo Clinic, 200 First Street SW,Rochester, Minnesota 55905 USA

Canadian Journal of Urology 2005, 12(1), 2547-2552.

Abstract

Purpose: To examine the change of hemoglobin in relation to testosterone level in non-metastatic prostate cancer patients receiving 2-year androgen suppression.
Methods and materials: A cohort of 72 patients, as participants of a phase II study, were treated with adjuvant radiotherapy plus 2-year androgen suppression after surgery to reduce the risk of relapse. Patients had laboratory tests including hemoglobin (Hb) and testosterone, and a quality of life questionnaire at regular intervals during the androgen suppression and post-androgen suppression period. The pattern of the change in Hb was evaluated in relation to testosterone level. The clinical significance of Hb change was assessed with a correlation analysis between Hb and the three domains of the questionnaire (global health status, physical functioning, and fatigue).
Results: Median age was 64.2 years. Median follow-up was 37 months. Mean Hb at the baseline was 148.4 g/L. It declined slightly with radiotherapy by 2.2 g/L. Maximal Hb decline during androgen suppression was 10.5 g/L (p<0.0001), occurring at 24 months after the initiation of androgen suppression. In most patients, Hb decline was <20 g/L. In the post-androgen suppression period, the recovery of Hb was slow and followed that of testosterone. The three quality of life domains did not show any significant correlation with the change in Hb.
Conclusion: The decline and recovery of Hb was closely related to that of testosterone. Two-year androgen suppression resulted in a statistically significant decline of Hb, which had, however, no clinically apparent adverse effect on the three quality of life domains.

Keywords

prostate cancer, anemia, hemoglobin,androgen suppression

Cite This Article

APA Style
Choo, R., Chander, S., Danjoux, C., Morton, G., Pearce, A. et al. (2005). How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?. Canadian Journal of Urology, 12(1), 2547–2552.
Vancouver Style
Choo R, Chander S, Danjoux C, Morton G, Pearce A, Deboer G, et al. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?. Can J Urology. 2005;12(1):2547–2552.
IEEE Style
R. Choo et al., “How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?,” Can. J. Urology, vol. 12, no. 1, pp. 2547–2552, 2005.



cc Copyright © 2005 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 41

    View

  • 29

    Download

  • 0

    Like

Share Link